82 related articles for article (PubMed ID: 10938969)
1. Treatment of post transfusion graft-versus-host disease.
Juji T; Nishimura M; Tadokoro K
Vox Sang; 2000; 78 Suppl 2():277-9. PubMed ID: 10938969
[TBL] [Abstract][Full Text] [Related]
2. Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor.
Ryo R; Saigo K; Hashimoto M; Kohsaki M; Yasufuku M; Watanabe N; Okada M; Tadokoro K; Juji T
Vox Sang; 1999; 76(4):241-6. PubMed ID: 10394145
[TBL] [Abstract][Full Text] [Related]
3. An immunohistological study of post-transfusion graft-versus-host disease (GVHD).
Hojo H; Kainuma Y; Kunori T; Wachi E; Wakasa H
Fukushima J Med Sci; 1993 Dec; 39(2):77-87. PubMed ID: 7927138
[TBL] [Abstract][Full Text] [Related]
4. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature.
Agbaht K; Altintas ND; Topeli A; Gokoz O; Ozcebe O
Transfusion; 2007 Aug; 47(8):1405-11. PubMed ID: 17655584
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of azidothymidine on resting and activated cells: potentiality of this drug for treatment of post-transfusion graft-versus-host disease.
Nishimura M; Hidaka N; Akaza T; Tadokoro K; Juji T
Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):131-8. PubMed ID: 9667067
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategy for post-transfusion graft-vs.-host disease.
Saigo K; Ryo R
Int J Hematol; 1999 Apr; 69(3):147-51. PubMed ID: 10222651
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute post-transfusion- graft-versus-host disease (GVHD) with intravenous human immunoglobulins: a case report.
Orlandi C; Frassetto A; Gnucci E; Lehmann JR; Neri R; Melandri D
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):760-1. PubMed ID: 16836524
[No Abstract] [Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Prevention of post-transfusion graft-versus-host disease.
Tasaki T; Ohto H; Abe R
Fukushima J Med Sci; 1993 Dec; 39(2):109-11. PubMed ID: 7927133
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of post-transfusion graft-versus-host disease after formalin-fixation.
Ryo R; Goto M; Takada M; Saigo K; Yamaguchi N; Hayashi M; Ito H; Onoyama H; Saito Y; Uchida S
Int J Hematol; 1994 Jun; 59(4):297-302. PubMed ID: 8086623
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-associated graft-versus-host disease.
Ohmori K; Sato H; Furukawa H; Sagara H; Kanno M
Fukushima J Med Sci; 1993 Dec; 39(2):89-94. PubMed ID: 7927139
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment for graft-versus-host disease after liver transplantation: two case reports.
Wang B; Lu Y; Yu L; Liu C; Wu Z; Liu X
Transplant Proc; 2007 Jun; 39(5):1696-8. PubMed ID: 17580224
[TBL] [Abstract][Full Text] [Related]
13. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
Garban F; Drillat P; Makowski C; Jacob MC; Richard MJ; Favrot M; Sotto JJ; Bensa JC; Cahn JY
Haematologica; 2005 Aug; 90(8):1096-101. PubMed ID: 16079109
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells.
Miura Y; Ueda M; Takami A; Shiobara S; Nakao S; Hess AD
Bone Marrow Transplant; 2003 Oct; 32(8):785-90. PubMed ID: 14520422
[TBL] [Abstract][Full Text] [Related]
16. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features in patients with hepatic graft-versus-host disease.
Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
[TBL] [Abstract][Full Text] [Related]
18. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
[TBL] [Abstract][Full Text] [Related]
19. Transfusion associated graft versus host disease.
Gupta A; Bansal D; Dass R; Das A
Indian Pediatr; 2004 Dec; 41(12):1260-4. PubMed ID: 15623910
[TBL] [Abstract][Full Text] [Related]
20. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study.
Or R; Gesundheit B; Resnick I; Bitan M; Avraham A; Avgil M; Sacks Z; Shapira MY
Transplantation; 2007 Mar; 83(5):577-81. PubMed ID: 17353777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
